title: Comparative adrenocortical suppression in dogs with otitis externa following topical otic administration of four different glucocorticoid-containing medications.
abstract: The safety of using otic formulations is often of concern for practitioners and pet owners alike, with "safe" in this context meaning no adrenocortical suppression. This study evaluated the effect of four glucocorticoid-containing otic formulations on plasma cortisol concentrations, measured by corticotropin stimulation testing (plasma cortisol concentrations before and after corticotropin injection), in dogs presented with otitis externa. Dexamethasone tended to have larger adrenocortical suppression compared with the other three formulations (betamethasone, triamcinolone, and mometasone), but the difference was not statistically significant. The largest difference among the four drugs was observed between dexamethasone and betamethasone (P=.09).
authors.affiliation: Animal Dermitology Clinic, Louisville, KY 40299, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Reeder
authors.forename: C E
authors.initials: CE
authors.lastname: Griffin
authors.forename: N L
authors.initials: NL
authors.lastname: Polissar
authors.forename: B
authors.initials: B
authors.lastname: Neradilek
authors.forename: R D
authors.initials: RD
authors.lastname: Armstrong
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000276:immunology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001623:Betamethasone / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D000068656:Mometasone Furoate; D010032:Otitis Externa / Q000188:drug therapy / Q000662:veterinary*; D011244:Pregnadienediols / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D016896:Treatment Outcome; D014221:Triamcinolone / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D014221:Triamcinolone; D003907:Dexamethasone; D001623:Betamethasone; D006854:Hydrocortisone